Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27298514 | 1.00 | PTGS2 (0.60) | PTGS2APPFBP1MAPTNPC1 | |
| SCHEMBL2544845 | 0.85 | PTGS2 (0.57) | PTGS2APPFBP1MAPTNPC1 | |
| SCHEMBL2544846 | 0.85 | PTGS2 (0.57) | PTGS2APPFBP1MAPTNPC1 | |
| SCHEMBL10557386 | 0.84 | APP (0.64) | PTGS2APPFBP1MAPTNPC1 | |
| SCHEMBL10557392 | 0.84 | APP (0.64) | PTGS2APPFBP1MAPTNPC1 | |
| SCHEMBL15689016 | 0.82 | PTGS2 (0.54) | PTGS2APPFBP1MAPTNPC1 | |
| SCHEMBL15689017 | 0.82 | PTGS2 (0.54) | PTGS2APPFBP1MAPTNPC1 | |
| SCHEMBL3120685 | 0.82 | PTGS2 (0.56) | PTGS2APPFBP1MAPTNPC1 | |
| SCHEMBL6437741 | 0.81 | PTGS2 (0.53) | PTGS2APPFBP1MAPTNPC1 | |
| SCHEMBL6437682 | 0.81 | PTGS2 (0.53) | PTGS2APPFBP1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20170260122-A1 | a-ASARY-LALDEHYDE ESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-14 | — | — | US | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110166141-A1 | CATHEPSIN S INHIBITORS | DCB-USA, LLC (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-7718685-B2 | 4,5-bis(4-methoxyphenyl)imidizole compound inducing differentiation of myoblasts or muscle fibers and pharmaceutical compositions including said compound | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2010-05-18 | — | — | US | disclosed |
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20070123576-A1 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | NFATC1, AIFM1, TP53 | PTGS2 2163/4885APP 690/4885FBP1 3999/4885 |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | PTGS2 1106/4885APP 2835/4885FBP1 243/4885 |
| US-20070123576-A1 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation | TNNC1, TNNI3, PYGM | PTGS2 1151/4885APP 984/4885FBP1 903/4885 |
| US-20170260122-A1 | a-ASARY-LALDEHYDE ESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | LSS, CYP51A1, BACE1 | PTGS2 1097/4885APP 4/4885FBP1 3343/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | PTGS2 734/4885APP 4774/4885FBP1 225/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | PTGS2 667/4885APP 1817/4885FBP1 825/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | PTGS2 51/4885APP 4385/4885FBP1 2197/4885 |
| US-20110166141-A1 | CATHEPSIN S INHIBITORS | CTSS, CTSV, CTSB | PTGS2 1514/4885APP 2104/4885FBP1 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.